Biography
David Deaton is a partner in the Corporate & Securities group at Jackson Walker. His primary focus is representing developers and equity sources in connection with structuring and drafting real estate joint ventures for the development and acquisition of multifamily, office and industrial projects. David provides what clients want most: expert advice on joint venture strategy, increased deal certainty, risk management, and the ability to realize the strategic and economic benefits of the joint venture.
David also represents private and public companies in connection with private placements of securities, corporate restructurings, mergers, acquisitions and divestitures and general corporate matters.
Education
B.A., University of Texas at Austin
M.S.C.J., Southwest Texas State University
J.D., magna cum laude, South Texas College of Law Houston
Bar Admissions
Texas, 1999
- Super Lawyers – Rising Stars, Thomson Reuters, 2005-2009
- Houston’s Top Lawyers, H Texas magazine, 2010
- Houston Professionals on the Fast Track, H Texas magazine, 2007, 2009
- State Bar of Texas
- Houston Bar Association – Corporate Section
September 24, 2020
Client Results‘Austin Business Journal’ Names Mixed-Use Development Financed by Jackson Walker Client Lionstone Investments the “Project of the Year” for 2020
Transformed from a 10-acre former rail yard to a mixed-use urban district with 800 apartment units and 115,000 square feet of retail over a three-year period, the Saltillo District has quickly developed into a new hub in Central Texas with one of the region’s most diverse mobility infrastructure programs.
August 22, 2017
Client ResultsJackson Walker Represents Buyer in Largest U.S. Ranch Sale of 2017
Jackson Walker’s real estate group has successfully represented the buyer of Cielo Vista Ranch, an 83,000-acre stretch of land in Southern Colorado.
January 14, 2013
Client ResultsJackson Walker Represents Pernix Therapeutics in $25 Million Acquisition Deal
Jackson Walker is representing Pernix Therapeutics Holdings, Inc. in its deal to acquire Somaxon Pharmaceuticals, Inc.